Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  International Immunopharmacology

• Publication date

  2009-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.intimp.2009.02.004PMID 19249390
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Optimisation of circulating biomarkers of cell death for routine clinical use.

  2008cited by this paper
• Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer.

  2008cited by this paper
• Cell death modalities: classification and pathophysiological implications

  2007cited by this paper
• Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma

  2007cited by this paper
• The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival.

  2007cited by this paper
• Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP

  2006cited by this paper
• Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles

  2006cited by this paper
• Response to Neoadjuvant Chemotherapy in Breast Cancer Could be Predictable by Measuring a Novel Serum Apoptosis Product, Caspase-Cleaved Cytokeratin 18: A Prospective Pilot Study

  2006cited by this paper
• Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP

  2005cited by this paper
• Validation of the English and Chinese versions of the Quick-FLIC quality of life questionnaire

  2005cited by this paper
• Keratin 8/18 breakdown and reorganization during apoptosis.

  2004cited by this paper
• A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera

  2003cited by this paper
• Measurement of an apoptotic product in the sera of breast cancer patients.

  2003cited by this paper
• [Study on expression of Ki-67, early apoptotic protein M30 in endometrial carcinoma and their correlation with prognosis].

  2003cited by this paper
• Active Caspases and Cleaved Cytokeratins Are Sequestered into Cytoplasmic Inclusions in Trail-Induced Apoptosis

  2000cited by this paper
• Immunocytochemical detection and mapping of a cytokeratin 18 neo‐epitope exposed during early apoptosis

  1999cited by this paper
• Caspase Cleavage of Keratin 18 and Reorganization of Intermediate Filaments during Epithelial Cell Apoptosis

  1997cited by this paper
• Apoptosis Generates Stable Fragments of Human Type I Keratins*

  1997cited by this paper
• Translational Therapeutics

  year unknowncited by this paper

• Hepatocyte-derived biomarkers predict liver-related events at 2 years in Child-Pugh class A alcohol-related cirrhosis.

  2023cites this paper
• The Response of Antioxidant Enzymes and Antiapoptotic Markers to an Oral Glucose Tolerance Test (OGTT) in Children and Adolescents with Excess Body Weight

  2023cites this paper
• Cell-free DNA Release in the Plasma of Patients with Cardiac Disease is Associated with Cell Death Processes

  2022cites this paper
• Prognostic biomarkers in lung cancer patients in terms of long-term survival

  2021cites this paper
• Usefulness of serum M30 and M65 levels to predict response to neoadjuvant chemotherapy in patients with breast cancer.

  2020cites this paper
• Systemic inflammation is associated with circulating cell death released keratin 18 fragments in colorectal cancer

  2020cites this paper
• Evaluation of serum M30 and M65 activity in patients with stage-I endometrial cancer

  2019cites this paper
• Cytokeratin 18 regulates the transcription and alternative splicing of apoptotic-related genes and pathways in HeLa cells

  2019cites this paper
• The roles of M30 and M65 in the assessment of treatment response and prognosis in patients with non-small cell lung cancer, who receive neoadjuvant treatment

  2019cites this paper
• Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients

  2018cites this paper
• Monitoring the response of head and neck tumour tissue to irradiation using a microfluidic-based approach

  2016cites this paper
• Can circulating M30 and M65 levels be beneficial markers in the diagnosis and management of patients with complete hydatidiform mole?

  2016cites this paper
• Circulating Levels of M30 and M65 Molecules in Transitional Cell Carcinoma of the Bladder and Their Relation to Tumor Progression

  2016cites this paper
• Diagnostic value of serum M30 and M65 in patients with nasopharyngeal carcinoma

  2015cites this paper
• The M30 assay does not detect apoptosis in epithelial-derived cancer cells expressing low levels of cytokeratin 18

  2015cites this paper
• Cytokeratin 18 for chemotherapy efficacy in gastric cancer

  2015cites this paper
• Clinical significance of serum M30 and M65 levels in patients with breast cancer.

  2014cites this paper
• Improving Topical Non-Melanoma Skin Cancer Treatment: In vitro Efficacy of a Novel Guanosine-Analog Phosphonate

  2014cites this paper
• Mechanistic biomarkers in acetaminophen-induced hepatotoxicity and acute liver failure: from preclinical models to patients

  2014cites this paper
• Clinical significance of serum M30 and M65 levels in melanoma

  2013cites this paper
• Cytokeratin 18 and h-FABP levels in intestinal ischemia–reperfusion injury: role of coenzyme Q10

  2013cites this paper
• Serum M65 as a biomarker for metastatic renal cell carcinoma.

  2013cites this paper
• Assessing the effects of radiotherapy on head and neck squamous cell carcinoma using microfluidic techniques

  2013cites this paper
• Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic biomarkers nucleosomes, DNAse, cytokeratin-18 fragments and survivin.

  2013cites this paper
• Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma

  2013cites this paper
• A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer

  2013cites this paper
• The oxidant/antioxidant status and cell death mode in oral squamous cell carcinoma

  2012cites this paper
• Prognostic importance of markers for inflammation, angiogenesis and apoptosis in high grade glial tumors during temozolomide and radiotherapy.

  2012cites this paper
• Serum M30 and M65 values in patients with advanced stage non-small-cell lung cancer compared with controls

  2012cites this paper
• Biological Functions of Cytokeratin 18 in Cancer

  2012cites this paper
• The prognostic significance of the increase in the serum M30 and M65 values after chemotherapy and relationship between these values and clinicopathological factors in patients with advanced gastric cancer

  2012cites this paper
• Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial

  2012cites this paper
• Cytokeratin 18 (CK18) and Caspase-Cleaved CK18 (ccCK18) as Response Markers in Anticancer Therapy

  2012cites this paper
• Cytokeratins - Tools in Oncology

  2012cites this paper
• Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?

  2011cites this paper
• Chemotherapy increases caspase-cleaved cytokeratin 18 in the serum of breast cancer patients

  2011cites this paper
• Application of the β-expectation tolerance interval to method validation of the M30 and M65 ELISA cell death biomarker assays.

  2011cites this paper
• Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer.

  2011cites this paper
• Utilization of cytokeratin-based biomarkers for pharmacodynamic studies

  2010cites this paper
• DISCOVERY AND VALIDATION OF PROTEIN BIOMARKERS FOR LUNG CANCER

  2010cites this paper
• Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer

  2010cites this paper
• Circulating Cytokeratin 18 Fragment M65—A Potential Marker of Malignancy in Colorectal Cancer Patients

  2009cites this paper
• Circulating apoptotic markers in the management of non-small cell lung cancer

  2009cites this paper